We confirmed that TET2 mutation had an unfavorable impact on RFS not OS in AML, not only in the total cohort, but also in the IR‐AML and CN‐AML subgroups, suggesting that the unfavorable impact of TET2 mutations was independent of cytogenetics. This evidence concerns the gene TET2 and acute myeloid leukemia.